Torrent Pharma Q4 Review: Motilal Oswal Maintains 'Neutral', Says Current Valuation Factors In Earnings Upside

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 

Motilal Oswal Report

Torrent Pharmaceuticals Ltd.’s Q4 FY25 performance was largely in line with our expectations. Healthy mid-teen YoY growth in US and domestic formulation was offset to some extent by currency headwinds in Brazil and modest YoY growth in Germany.

Torrent Pharma continues to focus on strengthening its branded business (73% of Q4 FY25 sales) in India/Brazil and ROW markets.

Specifically, in India, it has a multi-prong strategy – product launches in prescription and OTC segment, widening its reach, and adding MRs to support growth.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.